期刊文献+

培美曲塞联合顺铂与TP方案治疗晚期非小细胞肺癌疗效比较 被引量:4

Efficiency comparison between TP and pemetrexed plus cisplatin for advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:比较培美曲塞联合顺铂与多西紫杉醇联合顺铂(TP)方案治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:晚期NSCLC患者55例随机分成两组:培美曲塞联合顺铂组26例,TP组29例,两组均完成2个周期以上化疗。结果:培美曲塞联合顺铂组有效率为30.8%,TP组有效率为31.0%,两组近期有效率差异无统计学意义(P>0.05)。培美曲塞联合顺铂组白细胞减少及脱发发生率明显低于TP组(P<0.05),两组恶心、呕吐、血小板减少、肝功能受损、贫血、皮疹等不良反应无明显差异(P>0.05)。结论:培美曲塞联合顺铂方案治疗晚期NSCLC与TP方案的疗效相当,但不良反应相对较轻,可以作为临床一线方案推广。 Objective:To compare the efficiency of TP and pemetrexed plus cisplatin for advanced non-small cell lung cancer.Methods:Fifty-five patients with advanced NSCLC were randomly divided into pemetrexed plus cisplatin group(26 cases) and TP group(29 cases).The two groups underwent two courses of chemotherapy of pemetrexed plus cisplatin and TP regime respectively.Results:The effective rate of pemetrexed plus cisplatin group was 30.8% while that of TP group was 31.0%,the recent efficiency of the two groups was not significant different(P0.05).But incidence of white blood cell decrease and hair loss were significantly lower in pemetrexed plus cisplatin group than that in TP Group(P0.05).There were no significantly difference in incidence of nausea,vomiting,decreased platelets,liver function impairment and anemia(P0.05).Conclusions:Pemetrexed plus cisplatin shows comparable effects on NSCLC as TP regime,while the side effects were lighter than the latte.
出处 《海南医学院学报》 CAS 2012年第1期45-47,共3页 Journal of Hainan Medical University
基金 海南医学院科研基金资助学报项目(0020120012)~~
关键词 非小细胞肺癌 培美西塞 多西紫杉醇 顺铂 化疗 Non-small cell lung cancer Pemetrexed Docetaxel Cisplatin Chemotherapy
  • 相关文献

参考文献7

二级参考文献28

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2王莉.培美曲塞治疗非小细胞肺癌[J].癌症进展,2006,4(5):440-443. 被引量:10
  • 3Vogelzang NJ,Rusthoven JJ,Symanowski J,et al.Phase Ⅲ study of peme trexed incombination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21(14):2636.
  • 4Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589.
  • 5Manegold C,Gatzemeier vyon,Pawel J,et al.Front-linetreatment of advanced non-small-cell lung cancer with MTA (LY231514 pemetrexed disodium,ALIM-TA)and cisplatin:a muhicenter phaseⅡ tria1[J].Ann Oncol,2000,11(4):435.
  • 6von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality- of - life benefits in advanced non - small - cell lung cancer[J]. Br J Cancer, 2006, 95(8) : 966.
  • 7Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep, 1979, 63(11 - 12): 1727.
  • 8Sobieski M A, Graham J D, Pappas P S, et al. Reducing the effects of the systemic inflammatory response to cardiopul- monary bypass: can single dose steroids blunt systemic in- flammatory response syndrome[ J ]. ASAIO J, 2008, 54 (2) : 203.
  • 9Scagliotti G V, Parikh P, yon Pawel J. et al. Phase Ⅲ study comparing cisplatin plus gemeitabine with cisplatin plus peme- trexed in chemotherapy- naive patients with advanced - stage non small- cell lung cancer [ J ]. J Clin Oncol, 2008, 26 (21): 3543.
  • 10Hanna N, Shepherd F A, Fossella F V, et al, Randomized phase Ⅲ trial of pemetrexed versus docetaxal in patients with non- small - cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004, 22(9): 1589.

共引文献78

同被引文献44

  • 1王义善,王园园,姜鹏,马建军,曲震,王锡林,李军体,贾喜凤,王珊珊.射波手术平台对中晚期高难肿瘤患者的治疗分析[J].中华临床医师杂志(电子版),2011,5(19):5768-5771. 被引量:1
  • 2汪济东.DP、NP、GP和EP化疗方案治疗非小细胞肺癌的临床疗效与安全性对比分析[J].中华临床医师杂志,2013,7(5):1961-1964.
  • 3Jemal A. Global cancer statistics [ J ]. CA Cancer J Clin, 2011, 61 (2) : 69 -90.
  • 4Ide H. Therapeutic enhancement of S-1 with CPT-11 through down- regulation of thymidylate synthase in bladder cancer [ J ]. Cancer Med, 2013, 2(4) : 488 -495.
  • 5Lee DS, Kim YS, Kang JH, et al. Clinical Responses and PrognosticIndicators of Concurrent Chemoradiation for Non-small Cell LungCancer[J]. Cancer Res Treat, 2011,43(1):32-41.
  • 6Priker R, Minar W. Chemotherapy of advanced non-small cell lungcancer[J]. Front Radiat Ther Oncol, 2010,42:157-163.
  • 7Brade A, Bezjak A, Macrae R, et al. Phase I trial of radiationwithconcurrent and consolidationp emetxexed and cisplatin in patientswith unresectable stage IIIA/B non-small-cell lung cancer[J]. Int J Ra-diat Oncol Biol Phys, 2011,79(5):1395-1401.
  • 8Greenhalgh J, McLeod C, Bagust A, et al. Pemetrexed for the ma-in-tenance treatment of locally advanced or metastatic non-small celllung cancer[J]. Health Technol Assess, 2010,14(2):33-39.
  • 9Cardenal F, Amaiz MD, Mor d n T, et al. Phase I,study, of concurrentchemoradiation with pemetrexed and cisplatin followed by consolida-tion pemetrexed for patients with unresectable stage III non-small celllung cancer[J]. Lung cancer, 2011,74(1):69-74.
  • 10Paz-Ares L, De Marinis F, Dediu M, et al. Maintenance therapy withpemetrexed plus best supportive care versus placebo plus best sup-portive care after induction therapy with pemetrexed plus cisplatin foradvanced non-squamous non-small-cell lung cancer (PARA-MOUNT): a double-blind, phase 3, randomised controlled trial [J].Lancet Oncol, 2012,13(3):247-255.

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部